Trials / Completed
CompletedNCT05208398
Apixaban in Patients With Left Ventricular Thrombus
Apixaban in Patients With Left Ventricular Thrombus Post Myocardial Infarction; A Randomized Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Saud Al Babtain Cardiac Center · Other Government
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | 5 mg twice daily, on top of standards of care. |
| DRUG | Warfarin | Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations |
Timeline
- Start date
- 2018-02-18
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2022-01-26
- Last updated
- 2022-01-26
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT05208398. Inclusion in this directory is not an endorsement.